They are particularly important for patients who have certain comorbidities, such as cancer or multiple sclerosis,” Abbott Neuromodulation Business Medical Director Dr.
“MRIs have increasingly become an important tool helping doctors diagnose an illness or injury. The platform received FDA approval in September 2019.Īccording to a news release, the FDA’s expanded labeling covers the majority of Proclaim XR patients, offering higher quality images with faster MRI scan times. The Proclaim XR neurostimulation system combines low-energy therapy with a low-dosing protocol to relieve chronic pain while preserving its battery.
The new approval lifts MRI restrictions for lead tip location and the amount of radiofrequency power that can be used as part of the normal operating mode of an MRI scan. Abbott (NYSE:ABT) announced today that it received FDA approval for new magnetic resonance imaging (MRI) compatibility for the Proclaim system.įDA’s expanded approval covers MRI compatibility for the Proclaim XR spinal cord stimulation (SCS) system with Octrode leads.
